PDCD1 and breast carcinoma: In contrast to E0771 mammary carcinomas [46], MC38 CRCs established in immunocompetent C57BL/6 mice do not exhibit superior responses to the simultaneous administration of paclitaxel (20 mg/kg) and docetaxel (10 mg/kg) in combination with a PD-1 blocker, a lack of therapeutic interaction that appears to be accompanied by scarce recruitment of tumor-infiltrating lymphocytes to the tumor bed [90].